Solid Tumor Translational Research

STTR Website Quick Links

STTR researchers and clinicians believe
promising cancer therapies are on the
horizon.  Learn more about the solid tumor
cancer programs by clicking below.   

Read our annual report >

The Solid Tumor Translational Research (STTR) is a multidisciplinary and multi-organizational effort of physicians and scientists from Fred Hutch, UW Medicine and Seattle Cancer Care Alliance. The primary goal is to translate laboratory sciences into the most precise treatment options for patients with solid tumor cancers.

Together these leading cancer research and clinical care organizations are enhancing our knowledge of cancer using population research, preclinical cancer biology, translational, imaging and clinical studies of solid tumors.

Fred Hutch, world renowned for its research and treatment of cancers of the blood, has committed to increasing the ongoing research on solid tumor cancer biology that is being done in the Basic Sciences, Human Biology and Clinical Research divisions, as well as the excellent population-based research on solid tumors done in the Public Health Sciences Division.  The goal is to translate this focused commitment to advances in solid tumor treatment.


Revolutionizing solid tumor cancer treatment

Launched by Dr. Eric Holland, the STTR sets the stage for collaborations where scientists share insights into how to improve treatment for many tumors, leading to discoveries that can be applied to cancer. It’s the best shot at making headway against the disease.

Starting with brain, Holland is building a database based on thousands of tumor samples from patients. The database will contain complete genetics profiles for each tumor, plus information on how each patient was treated and responded. Eventually the database will be expanded to breast, colon, head and neck, lung, ovarian, pancreas and prostate. The goal is to profile tumors for every patient which can be compared to those in the database and inform the decision on the most effective therapy.

"This is personalized medicine - making decisions that are tailored to the tumor," Holland said.